WCN26-2145 IMPACT OF HISTOLOGY ON EFFICACY OF SPARSENTAN THERAPY IN IGA NEPHROPATHY: CENTRAL BIOPSY REVIEW OF PATIENTS IN THE PROTECT TRIAL

Read full text Summarise with VIRAT
Authors: Alex Mercer, Bruce M. Hendry, Stephanie Moody, Edward Murphy, Radko Komers, Ian S D Roberts
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In PROTECT, sparsentan, a non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA), resulted in significant reduction in proteinuria and preservation of kidney function when compared to irbesartan in adults with IgA nephropathy. Here we investigate the impact of biopsy histology of PROTECT participants on the clinical efficacy of sparsentan.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104302–104302
Publication date
25 March 2026
Language
EN